Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (NCT00037583)
The primary objectives are to establish the maximum tolerated dose or MTD of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in combination with cytarabine (DepoCyt®; Sigma Tau Pharmaceuticals) and daunorubicin (DaunoXome®; Gilead Sciences Inc.), as well as to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.
This trial is sponsored by Pfizer/Wyeth-Ayerst Laboratories. 
- Condition: Acute Myeloid Leukemia
- Phase: II
- Enrollment: 69
- Completion: September 2003
- Last verified: August 2009
Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.